Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7248824 intrathecal PET distribution study in healthy male volunteers
NL-OMON52457Completed
- Sponsor
- Roche
- Start
- Mar 2021
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Open-label trial of rugonersen in Angelman syndrome (AS), sponsored by Roche. Started Mar 2021; status: completed.
02
Drugs
rugonersen
03
Conditions
Angelman syndrome (AS)
Beyond the preview
Go deeper on NL-OMON52457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52457.